PofoliaShared via Pofolia

ACS Catalysis· 2026Q1

Enantioconvergent Assembly of Chiral Difluoromethyl Stereocenters by Nickel-Catalyzed Reductive Cross-Coupling

Zhiheng Li, Bo-heng Zhu, Lijun Tang, Xiao-Kang Dai et al.

Short summary

A nickel-catalyzed method creates chiral difluoromethyl-containing molecules with high enantioselectivity using a novel difluoromethyl alkyl triflate reagent.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Developed a nickel-catalyzed enantioconvergent reductive cross-coupling for chiral difluoromethyl stereocenters.
  • Utilizes a modular difluoromethyl alkyl triflate reagent derived from simple aldehydes.
  • Achieves broad substrate scope, good functional-group compatibility, and high enantioselectivity.
  • Demonstrates utility in late-stage difluoroalkylation of bioactive molecules and synthesis of drug analogues.

AI-generated from the title and abstract; the full text is not read.

Abstract

Abstract The catalytic asymmetric construction of C(sp3)–CF2H stereocenters remains a longstanding challenge in synthetic and medicinal chemistry. Herein, we report a nickel-catalyzed enantioconvergent reductive cross-coupling strategy that enables efficient access to chiral difluoromethyl-containing molecules from readily available starting materials. Central to this approach is a modular difluoromethyl alkyl triflate reagent, which can be prepared in two steps from simple aliphatic aldehydes and serves as an effective CF2H radical precursor under reductive nickel catalysis. In the presence of a rationally developed BiOx ligand, the reaction proceeds under mild conditions with broad substrate scope, good functional-group compatibility, and high enantioselectivity. The synthetic utility of this method is further demonstrated through late-stage asymmetric difluoroalkylation of complex bioactive molecules and concise access to chiral difluoromethyl analogues of a DprE1 inhibitor. This work establishes a general platform for catalytic asymmetric radical difluoroalkylation and provides promising opportunities for the discovery of chiral fluorinated pharmaceuticals.

The authors' abstract, as published at the source. ACS Catalysis, 2026 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pharmaceutical Science

Pharmaceutical SciencePharmacology, Toxicology and Pharmaceutics